{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:05:19Z","timestamp":1772247919578,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.urolonc.2009.02.012","type":"journal-article","created":{"date-parts":[[2009,4,23]],"date-time":"2009-04-23T04:55:52Z","timestamp":1240462552000},"page":"259-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder"],"prefix":"10.1016","volume":"29","author":[{"given":"Sarel","family":"Halachmi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boaz","family":"Moskovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Maffezzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giario","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kedar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro D.","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Nativ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2009.02.012_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-Year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib2","first-page":"3","article-title":"Guideline on Ta-T1 non-muscle invasive bladder cancer, update 2008","author":"Babjuk","year":"2008","journal-title":"European Association of Urology Guidelines"},{"key":"10.1016\/j.urolonc.2009.02.012_bib3","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update 2","volume":"178","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-5347(05)64045-1","article-title":"Complications of radical cystectomy for nonmuscle invasive disease: Comparison with muscle invasive disease","volume":"169","author":"Cookson","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib5","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.urology.2003.10.036","article-title":"Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer","volume":"63","author":"Gofrit","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2009.02.012_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/annonc\/mdi124","article-title":"Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients","volume":"16","author":"Moskovitz","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O'Donnell","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-5347(17)43864-X","article-title":"Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavorable tumor?","volume":"137","author":"Jakse","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib10","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: A decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2009.02.012_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jjco\/hyh030","article-title":"Fifteen years experience on intravesical therapy of T1G3 urinary bladder cancer: Conservative approach","volume":"34","author":"Cheng","year":"2003","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.urology.2006.09.019","article-title":"Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by bacille Calmette-Guerin immunotherapy","volume":"69","author":"Margel","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2009.02.012_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0090-4295(99)00116-8","article-title":"Intravesical bacille Calmette-Guerin in Stage T1 grade 3 bladder cancer therapy: A 7-year follow-up","volume":"54","author":"Hurle","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2009.02.012_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000019664","article-title":"Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: Recurrence, progression, and success","volume":"34","author":"Lebret","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-Year experience","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2009.02.012_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0090-4295(01)01324-3","article-title":"Tumor progression and survival in patients with T1G3 bladder tumors: Multicentric retrospective study comparing 94 patients treated during 17 years","volume":"58","author":"Patard","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2009.02.012_bib17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1464-410X.2004.04556.x","article-title":"T1G3 transitional cell carcinoma of the bladder: Recurrence, progression, and survival","volume":"93","author":"Peyromaure","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2009.02.012_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.0306-5251.2001.01449.x","article-title":"Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma","volume":"52","author":"Paroni","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00345-007-0143-1","article-title":"The influence of thermochemotherapy on bladder tumours: An immunohistochemical analysis","volume":"25","author":"van der Heijden","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib20","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)67523-4","article-title":"Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin","volume":"163","author":"Brake","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000090870","article-title":"Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: A pilot study","volume":"76","author":"Gacci","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2009.02.012_bib22","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.02.012_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143909000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143909000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:56:35Z","timestamp":1761040595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143909000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1078143909000702"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2009.02.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2009.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}